CLADRIBINE
Showing 51 - 75 of 172
High Risk Acute Myeloid Leukemia, Allogeneic Hematopoeitic Stem Cell Transplantation Trial in Shanghai (Cladribine, Fludarabine,
Recruiting
- High Risk Acute Myeloid Leukemia
- Allogeneic Hematopoeitic Stem Cell Transplantation
- Cladribine
- +3 more
-
Shanghai, Shanghai, ChinaShanghai general hospital, Shanghai Jiaotong university school o
Oct 10, 2021
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Trial (Cladribine)
Not yet recruiting
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Cladribine
- (no location specified)
Dec 17, 2020
Suboptimally Controlled Participants Previously Taking
Active, not recruiting
- Multiple Sclerosis
- Cladribine Tablets
-
Cullman, Alabama
- +38 more
Jul 19, 2022
Acute Myeloid Leukemia Trial in Poland, United States (A arm (DA-90), B arm (DAC), A arm (CLAG-M))
Recruiting
- Acute Myeloid Leukemia
- A arm (DA-90)
- +3 more
-
New York, New York
- +9 more
Sep 30, 2021
Suboptimally Controlled Participants Previously Taking Oral or
Recruiting
- Multiple Sclerosis
- Cladribine Tablets
-
Cullman, Alabama
- +66 more
Nov 29, 2022
Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow
Recruiting
- Acute Myeloid Leukemia
- +6 more
- Cladribine
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2022
Refractory Leukemia Trial in Shanghai (CALGE-VEN- RIC-MBF)
Recruiting
- Refractory Leukemia
- CALGE-VEN- RIC-MBF
-
Shanghai, Shanghai, China
- +2 more
May 22, 2023
Relapsing-Remitting Multiple Sclerosis Trial in Worldwide (Cladribine, Placebo)
Completed
- Relapsing-Remitting Multiple Sclerosis
- Cladribine
- Placebo
-
Boulder, Colorado
- +116 more
Nov 10, 2020
Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma Trial in Tucson (rituximab, bortezomib, cladribine)
Completed
- Lymphoma
- +3 more
- rituximab
- +2 more
-
Tucson, ArizonaThe University of Arizona Cancer Center
Dec 16, 2019
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in United
Recruiting
- Relapsing Multiple Sclerosis
- +2 more
- Autologous Hematopoietic Stem Cell Transplantation
- Best Available Therapy (BAT)
-
Palo Alto, California
- +20 more
Jan 25, 2023
Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Trial in Houston (drug, other, biological)
Recruiting
- Hairy Cell Leukemia
- Recurrent Hairy Cell Leukemia
- Cladribine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Mar 20, 2020
Registry of Multiple Sclerosis Participated in Cladribine
Completed
- Multiple Sclerosis
-
Cambridge, MassachusettsOutcome Sciences, Inc
Oct 24, 2019
Acute Myeloid Leukemia Trial in Hangzhou (D-CLAG)
Recruiting
- Acute Myeloid Leukemia
- D-CLAG
-
Hangzhou, Zhejiang, Chinathe First Affiliated Hospital,School of Medicine, Zhejiang Unive
Sep 12, 2020
Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Tumor Trial in
Completed
- Blasts 10 Percent or More of Bone Marrow Nucleated Cells
- +8 more
- Cladribine
- +13 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 11, 2021
Acute Myeloid Leukemia, Relapse Leukemia Trial in Guangzhou (Cladribine, G-CSF, Aclarubicin)
Unknown status
- Acute Myeloid Leukemia
- Relapse Leukemia
- Cladribine
- +3 more
-
Guangzhou, Guangdong, ChinaLiang Wang
Aug 18, 2019
Acute Lymphoblastic Leukemia Trial in GuangZhou (Cladribine, G-CSF, Cytarabine)
Unknown status
- Acute Lymphoblastic Leukemia
- Cladribine
- +3 more
-
GuangZhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 18, 2019
Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome Trial in Seattle
Completed
- Acute Biphenotypic Leukemia
- +5 more
- Cladribine
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 26, 2019
Multiple Sclerosis Trial in Worldwide (Mavenclad®)
Completed
- Multiple Sclerosis
-
Sydney, New South Wales, Australia
- +53 more
Jul 25, 2022
Multiple Sclerosis, Relapsing-Remitting Trial in United Kingdom, United States (Early Highly Effective Therapies Group,
Recruiting
- Multiple Sclerosis, Relapsing-Remitting
- Early Highly Effective Therapies Group
- Escalation Therapies Group
-
Aurora, Colorado
- +30 more
Jul 22, 2022
Acute Myeloid Leukemia Trial in Suzhou (IAC regimen, High-dose IA regimen, Intermediate-dose IA regimen)
Recruiting
- Acute Myeloid Leukemia
- IAC regimen
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Feb 3, 2020
Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia Trial in
Completed
- Mixed Phenotype Acute Leukemia
- +6 more
- Cladribine
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Feb 21, 2020
Acute Myeloid Leukemia Trial in Saint Louis (Selinexor, Cladribine, G-CSF)
Completed
- Acute Myeloid Leukemia
- Selinexor
- +4 more
-
Saint Louis, MissouriWashington University School of Medicine
Mar 6, 2020